Recombinant Human uPAR Protein (C-6His)

Name: Recombinant Human uPAR Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0437NP
Availability: InStock

BL-0437NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Other recombinant proteins, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Urokinase Plasminogen Activator Surface Receptor is produced by our Mammalian expression system and the target gene encoding Leu23-Arg303 is expressed with a 6His tag at the C-terminus.
Accession	Q03405
Synonym	Urokinase Plasminogen Activator Surface Receptor; U-PAR; uPAR; Monocyte activation antigen Mo3; CD87; PLAUR; MO3; UPAR
Gene Background	The Urokinase Type Plasminogen Activator (uPA) receptor (uPAR) is a widely expressed receptor for urokinase plasminogen activator (uPA) and pro-uPA. uPAR / CD87 is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. uPAR is expressed by T-cells, NK cells, monocytes, and neutrophils as well as non-hematopoietic cells that include vascular endothelial cells, fibroblasts, smooth muscle cells, keratinocytes, placental trophoblasts, hepatocytes, and a wide variety of tumor cells (including breast, colon, and prostate carcinoma, melanoma). It plays a critical role in the regulation of cell-surface plasminogen activation in physiological and pathological conditions, and it is also involved in cellular adhesion, the transmission of extracellular signals across the plasma membrane and the subsequent regulation of gene expression. uPAR has been implicated in several biological processes including angiogenesis, monocyte migration, cancer metastasis, trophoblast implantation, and wound healing. Human uPAR is encoded as a 313 amino acid residue polypeptide, excluding a 22 residue signal peptide and shows 60-70% similarity with the murine uPAR amino acid sequence although binding of uPA to uPAR shows strong species specificity.
Molecular Mass	32.4 KDa
Apmol Mass	52 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.
Subcellular Location	Cell membrane. Cell projection, invadopodium membrane.; [Isoform 1]: Cell membrane; Lipid-anchor, GPI-anchor.; [Isoform 2]: Secreted.
Database References	HGNC: 9053 OMIM: 173391 KEGG: hsa:5329 STRING: 9606.ENSP00000339328 UniGene: Hs.466871
Tissue Specificity	Expressed in neurons of the rolandic area of the brain (at protein level). Expressed in the brain.

Gene Functions References

In acutely admitted patients with COPD, elevated PLAUR levels were associated with increased risk of mortality. PMID: 29783959
This study shows that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
High expression of U-PAR is associated with breast cancer. PMID: 29893327
suPAR is associated with the Coronary Artery Calcification score and is a risk factor for new-onset CVD in patients undergoing hemodialysis. PMID: 29734173
Elevated baseline soluble urokinase receptor concentrations independently associate with new-onset microalbuminuria in subjects at increased risk of developing type 2 diabetes. PMID: 28091558
suPAR levels were significantly higher Behcet's disease patients. PMID: 27171829
To develop enzyme-resistant analogues, we applied here the Retro-Inverso (RI) approach, whereby the topology of the side chains is maintained by inverting the sequence of the peptide and the chirality of all residues. Molecular dynamics suggests that peptide RI-3 adopts the turn structure typical of uPAR-FPR1 antagonists PMID: 28465589
results demonstrated that PLAUR induces geftinib-resistance through EGFR/p-AKT/survivin signaling pathway in gefitinib-resistant human lung adenocarcinoma cells. PLAUR could be a novel therapeutic target for gefitinib-resistant NSCLC patients. PMID: 29961070
High Upar expression is associated with breast cancer. PMID: 28498427
Circulating soluble uPAR levels are higher in patients with peripheral arterial disease, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes. PMID: 28728756
Data confirmed PLAUR and CDH11, both targets of miR-335, to be overexpressed in gastric cancer tissues. PMID: 29075357
Serum and urine concentration of suPAR did not different between different clinical patterns of nephrotic syndrome in children, regardless the immunosuppressive treatment used. PMID: 29775445
the present study demonstrated that EGF induced aggressiveness of gastric cancer cells by activating epithelial to mesenchymal transition, which involved the activation of the ERK1/2 pathway and, subsequently, uPAR expression PMID: 28849196
The results establish GDE3 as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior. PMID: 28849762
uPAR and TF could potentially be attractive targets for molecular imaging and therapy in oral squamous cell carcinoma due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. PMID: 28841839
suPAR levels are significantly elevated in hemodialysis patients with ESRD and remain associated with adverse outcomes. PMID: 28495863
These findings may show that presenting a high level of suPAR in migraine patients with attack and aura results to predisposition to occurring on the symptoms and that high levels of suPAR, procalcitonin and fibrinogen in patients with migraine result in neurogenic inflammation during migraine headaches. PMID: 28553881
suPAR may be a good novel biomarker for systemic subclinical inflammation and immune activation linked to adolescent obesity. PMID: 28749394
IFN-gamma, CXCL16 and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in systemic lupus erythematosus. PMID: 28628472
Main associations between PLAUR (urokinase plasminogen activator receptor) single nucleotide polymorphisms (SNPs) and markers of airway remodelling, and immunohistochemical analyses PMID: 26869673
Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in basal cell carcinomas. PMID: 28429105
Plasma plasminogen activator urokinase receptor (P-suPAR) concentrations are elevated in acute alcohol pancreatitis (AAP) and correlate with the severity of the disease, suggesting P-suPAR may serve as a prognostic marker for AAP severity on admission. PMID: 27841794
We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR and uPAR . Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR targeting, supporting further translation for patients with sarcomas and other EGFR-expressing malignancies. PMID: 28193671
Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). PMID: 28316028
Sera and tissues from malignant mesothelioma (MM) patients showed significantly high plasminogen activator urokinase receptor (uPAR) levels, suggesting the pathogenic role of uPAR in the tumor biology of MM. PMID: 27602956
Levels of circulating cleaved soluble forms plasminogen activator urokinase receptor (DIIDIII-suPAR) in acute myeloid leukemia (AML) patients are higher as compared to controls and significantly decrease after the conditioning. PMID: 27517491
Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication PMID: 27759946
Binding of uPAR to VN triggers integrin-mediated signals, which result in ERK1-2 and RAC activation, accumulation of ROS, and senescence. PMID: 28086938
Plasma levels of intact and cleaved urokinase plasminogen activator receptor do not hold important predictive or prognostic information in men with clinically localised prostate cancer. PMID: 28607123
This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. PMID: 27624865
uPAR and mTORC2 are components of a single cell-signaling pathway. PMID: 27777073
Patients with high suPAR levels were more likely to have progression of their kidney disease. PMID: 28873129
Results provide evidence that uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. PMID: 27502396
PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1); maintenance of cell cycle arrest after DNA damage in a TP53-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 recombinase, the principal protein involved in the homologous recombination repair pathway. PMID: 27685627
The synergy of circulating factor suPAR and APOL1 G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD. PMID: 28650456
Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP PMID: 28393357
This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS cells, is mediated by the EP2 receptor-dependent Src/EGFR/JNK1/2, Erk1/2/AP-1, and Src/EGFR/JNK1/2, Erk1/2/NF-kappaB cascades. PMID: 27377703
Studies indicate the feasibility of combining two U-PA receptor (uPAR)-targeted probes in a preclinical head and neck cancer model. PMID: 28039488
Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis. PMID: 27914940
our study indicates that suPAR increases in patients with AML and this situation is associated with poorer survival. suPAR can thus be used as a diagnostic and prognostic biomarker in AML and may help in the developing of specific therapeutic targets. PMID: 26376588
urokinase plasminogen activator receptor has a role in incidence of venous thromboembolism PMID: 26466866
Our study implies that both soluble UPAR and advanced echocardiography are useful diagnostic tools for identifying patients with diabetes at risk of future clinical heart disease PMID: 26951602
The effect of LIF and uPAR on trophoblast migration and invasion was mediated by PI3K/AKT signaling pathway. PMID: 27133045
findings showed that elevated plasma suPAR levels were independently associated with an increased risk of developing first-time myocardial infarction in an HIV-1-infected population PMID: 26365671
Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker for prognosticating cardiovascular disease PMID: 27052059
we review the human and mouse Ly6/uPAR family gene and protein structure and genomic organization, expression, functions, and evolution, and introduce new names for novel family members PMID: 27098205
Report presence of urokinase-type plasminogen activator receptor in seminal plasma, focusing on its interesting role as reliable and sensitive marker of inflammation for the differential diagnosis of male accessory gland inflammation. PMID: 26384478
uPAR expression is higher in normal pregnant women than that in patients with threatened abortion. uPAR promotes trophoblast migration and invasion during embryo implantation as well as plays a role in trophoblast differentiation into syntrophoblasts. PMID: 26823748
results show that cleaved uPAR forms are significantly increased in patients with advanced prostate cancer. PMID: 26764285
Hypoxia enhanced the endogenous uPAR mRNA and protein expression.HIF-1 protein bound the putative HIF-1 response element on the uPAR promoter.uPAR protein expression was detected in cervical cancer but not in normal cervix or CIN. PMID: 26718775

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.